Related Experiment Video
Updated: Mar 12, 2026

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years
Joseph P Bradley1, Emily M Barrow2, Edie R Hapner3
1Department of Otolaryngology-Head & Neck Surgery, Washington University in St. Louis School of Medicine, St. Louis, Missouri.
Objectives:
This study aimed to identify the changes in dosing of botulinum toxin-A for adductor spasmodic dysphonia (ADSD) over a prolonged period.
Study Design:
This is a retrospective chart review.
Methods:
One hundred thirteen subjects treated for ADSD from 2003 to 2013 were identified from a clinical database. Subject age, gender, and total injection dose amount were all recorded for all subjects who had at least 10 injections.
Results:
Fifty-four subjects met criteria for inclusion. There were no age or gender differences in the starting dose for subjects. Dosing decreased significantly compared with the second dose (5.05 ± 1.623 Units), by the sixth dose (4.26 ± 1.698 Units), and continued through the 10th dose (4.08 ± 2.019 Units) (P < 0.005 for all).
Conclusions:
Botulinum toxin-A dosing for ADSD decreases consistently over subsequent injections after the initial two dose titrations.
More Related Videos
Related Concept Videos
Skeletal Muscle Relaxants: Therapeutic Uses
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Depolarizing Blockers: Pharmocokinetics
Direct-Acting Cholinergic Agonists: Therapeutic Uses

